Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance
This Funding Opportunity Announcement (FOA) invites applications to establish research teams of the Small-Cell Lung Cancer (SCLC) Consortium to conduct research whose overall goals are: 1) to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations; and/or, 2) to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy.
This FOA focuses on two of the five research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Small Cell Lung Cancer (SCLC). Additional priorities of the Framework are stated in this FOA, as studies are expected to use or develop state-of-the-art research tools and –omic profiles to identify therapeutic strategies that are relevant to human SCLC disease progression and resistance.
The research supported by this FOA will be performed by individual research teams who are expected to collaborate with one another and with a central SCLC Coordinating Center. A third component of the SCLC Consortium focuses on prevention and early detection of SCLC.
Open Date (Earliest Submission Date) February 17, 2016
Letter of Intent Due Date(s) 30 days prior to the application due date
Application Due Date(s) March 17, 2016; November 17, 2016; March 17, 2017; November 17, 2017, March 17, 2018; November 17, 2018, by 5:00 PM local time of applicant organization.